RecruitingNot ApplicableNCT06059521

Software Refraction With Mobilerone Versus Retinoscopy

Randomized Controlled Study on Subjective Refraction by Software Eye Test Technology Versus Retinoscopy


Sponsor

Beijing Airdoc Technology Co., Ltd.

Enrollment

120 participants

Start Date

Jul 15, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Software refraction in the mobilerone for myopia and astigmatism is a novel medical device for myopia adults and elder children with or without astigmatism. And the investigators would like to test its accuracy and efficacy as well as safety.


Eligibility

Min Age: 10 YearsMax Age: 46 Years

Inclusion Criteria10

  • • subject with ametropia on each eye ≤-12.00D
  • subject with best corrected visual acuity ≥ 20/25, no amblyopia
  • subject with normal transparency of eyes
  • subject with a healthy fundus that does not reveal major abnormalities that may affect vision due to the fluctuate situations
  • subject able to cooperate with the screen and the operator
  • subject without heavy drug treatment that may affect vision as synthetic antimalarials, corticosteroids
  • non-diabetic subject
  • non nystagmus subject
  • non-strabismus subject
  • subject who has not had eye surgery less than 1 year old

Exclusion Criteria4

  • • subject with a topography showing an anomaly (keratoconus type or other)
  • subject with hyperopia or presbyopia
  • subject with mild myopia ≥ -1.00D
  • subject who cannot speak with the operator including those staff of local optometrists or ophthalmologists

Interventions

DEVICESoftware refraction with Eye Test Technology in a mobilerone

Refraction is done by software App by a mobilerone software installed.

DEVICERetinoscopy

Retinoscopy is an objective refraction method with retinoscope.


Locations(3)

Airdoc MPC Opthalmology Clinics

Beijing, Beijing Municipality, China

Jenny QIU

Beijing, Beijing Municipality, China

Qiu Jenny

Beijing, Haidian District, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06059521


Related Trials